|
|
|
Insider
Information: |
Priebe Waldemar |
Relationship: |
|
City: |
Houston |
State: |
TX |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
2,781,573 |
|
Indirect Shares
|
1,020,807 |
|
|
Direct
Value |
$7,065,195 |
|
|
Indirect Value
|
$2,220,762 |
|
|
Total
Shares |
3,802,380 |
|
|
Total
Value |
$9,285,958 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Moleculin Biotech, Inc. |
MBRX |
10% Owner |
2017-08-16 |
2,781,573 |
2016-06-02 |
864,000 |
Premium* |
|
Cns Pharmaceuticals, Inc. |
CNSP |
|
|
0 |
2023-03-28 |
156,807 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
22 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
CNSP |
Cns Pharmaceuticals, Inc. |
|
|
2023-03-28 |
4 |
S |
$1.04 |
$10,400 |
I/I |
(10,000) |
156,807 |
0 |
- |
|
CNSP |
Cns Pharmaceuticals, Inc. |
|
|
2023-03-27 |
4 |
S |
$1.09 |
$5,450 |
I/I |
(5,000) |
166,807 |
0 |
- |
|
CNSP |
Cns Pharmaceuticals, Inc. |
|
|
2023-03-24 |
4 |
S |
$1.08 |
$5,400 |
I/I |
(5,000) |
171,807 |
0 |
- |
|
CNSP |
Cns Pharmaceuticals, Inc. |
|
|
2023-03-23 |
4 |
S |
$1.08 |
$10,800 |
I/I |
(10,000) |
176,807 |
0 |
- |
|
CNSP |
Cns Pharmaceuticals, Inc. |
|
|
2023-03-22 |
4 |
S |
$1.08 |
$5,400 |
I/I |
(5,000) |
186,807 |
0 |
- |
|
CNSP |
Cns Pharmaceuticals, Inc. |
|
|
2023-03-21 |
4 |
S |
$1.10 |
$5,500 |
I/I |
(5,000) |
191,807 |
0 |
- |
|
CNSP |
Cns Pharmaceuticals, Inc. |
|
|
2023-03-20 |
4 |
S |
$1.08 |
$5,400 |
I/I |
(5,000) |
196,807 |
0 |
- |
|
CNSP |
Cns Pharmaceuticals, Inc. |
|
|
2023-03-17 |
4 |
S |
$1.13 |
$5,650 |
I/I |
(5,000) |
201,807 |
0 |
- |
|
CNSP |
Cns Pharmaceuticals, Inc. |
|
|
2023-03-16 |
4 |
S |
$1.24 |
$6,200 |
I/I |
(5,000) |
206,807 |
0 |
- |
|
CNSP |
Cns Pharmaceuticals, Inc. |
|
|
2023-03-15 |
4 |
S |
$1.22 |
$6,100 |
I/I |
(5,000) |
211,807 |
0 |
- |
|
CNSP |
Cns Pharmaceuticals, Inc. |
|
|
2023-03-14 |
4 |
S |
$1.35 |
$6,750 |
I/I |
(5,000) |
216,807 |
0 |
- |
|
CNSP |
Cns Pharmaceuticals, Inc. |
|
|
2023-03-13 |
4 |
S |
$1.30 |
$6,500 |
I/I |
(5,000) |
221,807 |
0 |
- |
|
CNSP |
Cns Pharmaceuticals, Inc. |
|
|
2023-03-10 |
4 |
S |
$1.29 |
$6,450 |
I/I |
(5,000) |
226,807 |
0 |
- |
|
CNSP |
Cns Pharmaceuticals, Inc. |
|
|
2022-12-09 |
4 |
S |
$2.43 |
$6,799 |
I/I |
(2,798) |
231,807 |
0 |
- |
|
CNSP |
Cns Pharmaceuticals, Inc. |
|
|
2022-12-08 |
4 |
S |
$2.40 |
$13,200 |
I/I |
(5,500) |
234,605 |
0 |
- |
|
CNSP |
Cns Pharmaceuticals, Inc. |
|
|
2022-12-07 |
4 |
S |
$2.46 |
$13,530 |
I/I |
(5,500) |
240,105 |
0 |
- |
|
CNSP |
Cns Pharmaceuticals, Inc. |
|
|
2022-12-06 |
4 |
S |
$2.47 |
$13,585 |
I/I |
(5,500) |
245,605 |
0 |
- |
|
MBRX |
Moleculin Biotech, Inc. |
10% Owner |
|
2016-06-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
864,000 |
|
- |
|
MBRX |
Moleculin Biotech, Inc. |
10% Owner |
|
2017-08-16 |
4 |
S |
$1.70 |
$170,300 |
D/D |
(100,000) |
2,781,573 |
0 |
- |
|
MBRX |
Moleculin Biotech, Inc. |
10% Owner |
|
2016-06-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,881,573 |
|
- |
|
CNSP |
Cns Pharmaceuticals, Inc. |
10% Owner |
|
2020-05-05 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,495,867) |
7,533,133 |
0 |
- |
|
CNSP |
Cns Pharmaceuticals, Inc. |
10% Owner |
|
2019-11-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
9,029,000 |
|
- |
|
22 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|